oncology
Cancer care

Company defends online marketing of CA125 ovarian cancer checks

An Australian company has defended its online promotion of CA125 “ovarian cancer check” tests. The company, i-screen, is marketing the CA125 test direct to consumers for $49, as one of a suite of tests to “track key biomarkers in your blood before they become an issue”. Consumers who buy the test online receive a pathology ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic